Several factors may contribute to the increased risk of cancer in patients with hypertension, including changes in the structure and function of the extracellular matrix (ECM) [8,9], increased activity of matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9 [7], elevated production and activity of vascular endothelial growth factor (VEGF) [10], oxidative stress [11,12], and dysfunction of the renin–angiotensin–aldosterone system (RAAS) [13]. This evidence concerns the gene VEGFA and Hypertension.